RecruitingPhase 1NCT07029555
An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis
A Phase Ib, Open-label, Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of PIT565 in Participants With Rheumatoid Arthritis (RA)
Sponsor
Novartis Pharmaceuticals
Enrollment
57 participants
Start Date
Jun 12, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of the study is to determine the safety, tolerability, and pharmacokinetics of PIT565, in participants with rheumatoid arthritis (RA).
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria2
- Signed informed consent must be obtained prior to participation in the study. Male and female patients, aged 18 to 75 years at screening, diagnosed with RA according to the 2010 ACR/EULAR or 1987 ACR classification at least 12 weeks prior to screening.
- Immunization (primary or from vaccinations) against pneumococcus, influenza, meningococcus and COVID-19 infection at least 2 weeks prior to the first dosing. Local guidelines should be followed to determine requirement for vaccination (or booster), as well as the type and schedule of vaccination.
Exclusion Criteria7
- • Any of the following cardiac conditions
- Unstable angina, myocardial infarction, coronary artery bypass graft (CABG), or stroke within 6 months prior to screening
- Clinically significant and/or uncontrolled heart disease such as congestive heart failure requiring treatment (NYHA Grade ≥ 2) or uncontrolled hypertension
- Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second or third degree atrioventricular block without a pacemaker
- History of familial long QT syndrome or known family history of Torsades-de- Pointes
- Resting QTcF ≥ 450 msec (male) or ≥ 460 msec (female) at screening
- Use of agents known to prolong the QT interval unless they can be permanently discontinued for the duration of the study.
Interventions
BIOLOGICALPIT565
Study treatment will be provided in vials as open-label participant specific supply.
Locations(12)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07029555
Related Trials
Targeted Remotely-delivered Anti-inflammatory Interventions With Exercise for Rheumatoid Arthritis
NCT068415621 location
A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis
NCT0710093829 locations
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT0381634552 locations
Biobank for Inflammatory Chronic Diseases and Osteoporosis
NCT050392161 location
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
NCT0691680633 locations